Clinical Trial News and Research

RSS

MJFF announces acquisition of parkin research tools from Imago Pharmaceuticals

The Michael J. Fox Foundation for Parkinson's Research announces the acquisition of a library of research tools around the parkin protein from Imago Pharmaceuticals. The Foundation believes these tools — cell lines, plasmids, compounds and more — will accelerate biological study and drug development against this promising disease-modification target.

11 May 2015

The Project Data Sphere® initiative achieves 1st year milestones

Cancer community broadly shares, integrates, and analyzes clinical trial data within a single research platform to advance innovation and improve lives...

11 May 2015

Nevro Q1 revenue increases 45% to $9.7 million

Nevro Corp., a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2015.

11 May 2015

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro Corp., a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the United States Food and Drug Administration for its Senza spinal cord stimulation (SCS) system.

10 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

Cholesterol-lowering statin drugs could delay prostate cancer growth in patients receiving ADT

Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.

8 May 2015

UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine's Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial.

8 May 2015

NIH-sponsored Phase 1 clinical trial evaluates novel investigational West Nile virus vaccine

A novel investigational West Nile virus vaccine discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University is being evaluated in an NIH-sponsored Phase 1, first-in-human, clinical trial at Duke University. Although several early-stage West Nile virus vaccine clinical trials have been completed to date, no human vaccine has been approved for commercial use.

7 May 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study.

7 May 2015

DePuy Synthes CMF introduces SYNTHECEL Dura Repair for use in neurosurgery

DePuy Synthes CMF today announced the launch of SYNTHECEL Dura Repair, the first commercially available biosynthesized dural replacement derived from cellulose for use in neurosurgery. DePuy Synthes CMF is a part of the DePuy Synthes Companies of Johnson & Johnson.

7 May 2015

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).

6 May 2015

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Juniper Pharmaceuticals, Inc., today announced financial results for the three-month period ended March 31, 2015.

6 May 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.

6 May 2015

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.

6 May 2015

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.

5 May 2015

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that activity and tolerance data for its second lead product Col-Treg were presented through a poster presentation at the 2015 ARVO Annual Meeting, May 3-7, 2015, in Denver, Colorado, US.

5 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Makindus, Inc. a specialty pharmaceutical development company focused on ophthalmology announced today that the European Medicines Agency has granted orphan drug designation for their lead candidate, MI-100, for the treatment of Stargardt's Disease.

4 May 2015

Keynote 24 study explores investigational approach to treating lung cancer

Lung cancer impacts the lives of millions of people worldwide. In nearly 40 percent of people diagnosed with lung cancer, it has metastasized, or spread to other areas of the body, making it difficult to treat. Immunotherapy is a type of therapy that uses the body's own immune system to help fight cancer. Immunotherapy may help the body's immune system target cancer cells.

30 Apr 2015

Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

Boston Scientific announces the signing of two strategic agreements to advance the company's efforts to bring value based solutions aimed at improving outcomes and reducing the cost of cardiovascular care delivery to healthcare systems.

30 Apr 2015

Clinical Trial News and Research

MJFF announces acquisition of parkin research tools from Imago Pharmaceuticals

The Project Data Sphere® initiative achieves 1st year milestones

Nevro Q1 revenue increases 45% to $9.7 million

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Cholesterol-lowering statin drugs could delay prostate cancer growth in patients receiving ADT

UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

NIH-sponsored Phase 1 clinical trial evaluates novel investigational West Nile virus vaccine

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

DePuy Synthes CMF introduces SYNTHECEL Dura Repair for use in neurosurgery

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

Researchers identify multiple types of resistance to new targeted lung cancer drug

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Keynote 24 study explores investigational approach to treating lung cancer

Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery